Literature DB >> 22236146

Prevalence and predictive factors of diabetes in hepatitis virus positive liver cirrhosis with fasting plasma glucose level of <126 mg/dL.

Naoki Matsumoto1, Yasuji Arase, Yuya Seko, Norihiro Imai, Yusuke Kawamura, Hitomi Sezaki, Tetsuya Hosaka, Norio Akuta, Mariko Kobayashi, Masahiro Kobayashi, Yoshiyuki Suzuki, Satoshi Saito, Fumitaka Suzuki, Kenji Ikeda, Hiromitsu Kumada, Kaoru Aida, Tetsuro Kobayashi.   

Abstract

AIM: The aim of this study was to evaluate the prevalence and predictive factors of diabetes in hepatitis virus positive liver cirrhotic patients with fasting plasma glucose (FPG) level of <126 mg/dL.
METHODS: A total of 263 patients with hepatitis C virus (HCV) or hepatitis B virus (HBV) positive liver cirrhosis, FPG level of <126 mg/dL, and had diabetes status evaluated by the use of 75-g oral glucose tolerance test (OGTT), were enrolled in this study. Plasma glucose and insulin levels were analyzed periodically for 3 h after oral glucose loading. Diabetes was defined as a 2-h post-load glucose on the OGTT of ≥200 mg/dL. The prevalence of diabetes by use of OGTT and predictive factors for diabetes were evaluated by the use of the Mann-Whitney U-test, Fisher's exact probability test or multivariate analysis by logistic regression. Hypoalbuminemia was defined as serum albumin level of <3.9 g/dL. Elevated indocyanine green retention rate at 15 min (ICG( R) 15) was regarded as ≥ 25%.
RESULTS: Out of 263 patients, 44 (16.7%) were diagnosed as having diabetes. Multivariate analysis showed that diabetes occurred when patients had hypoalbuminemia of <3.9 g/dL (odds ratio [OR] 2.33; 95% confidential interval [CI] = 1.04-5.24; P = 0.040) and ICG( R) 15 of <25% (OR 2.36; 95%CI = 1.01-5.58).
CONCLUSIONS: Hypoalbuminemia and elevated ICG( R) 15 in hepatitis virus related cirrhotic patients with FPG level of <126 mg/day enhance diabetes pattern after OGTT with significant difference.
© 2012 The Japan Society of Hepatology.

Entities:  

Year:  2012        PMID: 22236146     DOI: 10.1111/j.1872-034X.2011.00957.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  6 in total

Review 1.  Current Concepts in Diabetes Mellitus and Chronic Liver Disease: Clinical Outcomes, Hepatitis C Virus Association, and Therapy.

Authors:  Diego García-Compeán; José Alberto González-González; Fernando Javier Lavalle-González; Emmanuel Irineo González-Moreno; Jesús Zacarías Villarreal-Pérez; Héctor J Maldonado-Garza
Journal:  Dig Dis Sci       Date:  2016-02       Impact factor: 3.199

2.  The investigation of glucose metabolism and insulin secretion in subjects of chronic hepatitis B with cirrhosis.

Authors:  Chun-Hui Guo; Ting-Ting Sun; Xi-Ding Weng; Jian-Chun Zhang; Jian-Xin Chen; Guo-Jiong Deng
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

3.  Chronic hepatitis B virus infection status is more prevalent in patients with type 2 diabetes.

Authors:  Jun Lu; Xuhong Hou; Hong Tu; Zhenghao Tang; Yongbing Xiang; Yuqian Bao; Jianren Gu; Weiping Jia
Journal:  J Diabetes Investig       Date:  2017-03-13       Impact factor: 4.232

Review 4.  Diagnosis and Clinical Implications of Diabetes in Liver Cirrhosis: A Focus on the Oral Glucose Tolerance Test.

Authors:  Tsutomu Nishida
Journal:  J Endocr Soc       Date:  2017-05-23

5.  Differences in characteristics of glucose intolerance between patients with NAFLD and chronic hepatitis C as determined by CGMS.

Authors:  Tsunehiro Ochi; Takumi Kawaguchi; Takashi Nakahara; Masafumi Ono; Shuhei Noguchi; Yuichi Koshiyama; Kensuke Munekage; Eisuke Murakami; Akira Hiramatsu; Mitsunari Ogasawara; Akira Hirose; Hiroshi Mizuta; Kosei Masuda; Nobuto Okamoto; Narufumi Suganuma; Kazuaki Chayama; Masahiro Yamaguchi; Takuji Torimura; Toshiji Saibara
Journal:  Sci Rep       Date:  2017-08-31       Impact factor: 4.379

Review 6.  Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy.

Authors:  Sylvia Drazilova; Jakub Gazda; Martin Janicko; Peter Jarcuska
Journal:  Can J Gastroenterol Hepatol       Date:  2018-08-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.